CureVac (CVAC) has released an update.
CureVac N.V., a prominent mRNA biopharmaceutical firm, has announced unanimous shareholder support for all proposed agenda items at their annual general meeting. The approved measures included key appointments and reappointments to the company’s Management and Supervisory Boards and the reappointment of KPMG as external auditors for the 2024 financial year. CureVac, with over two decades of experience in mRNA technology, continues to pioneer in prophylactic vaccines and therapeutic treatments across various diseases.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
